For laboratory and research use only. Not for human consumption.
Comparison

Acetyl Tetrapeptide-5 vs Oligopeptide-1

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

Acetyl Tetrapeptide-5

Also: Eyeseryl, Ac-beta-Ala-His-Ser-His

Research

Acetyl tetrapeptide-5 is a short synthetic peptide sold by Lipotec (now Lubrizol) as Eyeseryl, made for eye creams that target under-eye puffiness. The pitch is that it reduces fluid leaking into the tissue under the eyes. It is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it.

Skin & HairLimited Research
Oligopeptide-1

Also: sh-Oligopeptide-1, rh-Oligopeptide-1

Clinical Trials

sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.

Skin & HairHuman Trials

Key Comparison Insights

  • Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
  • Oligopeptide-1 has stronger research evidence (Human Trials) compared to Acetyl Tetrapeptide-5 (Limited Research).

Detailed Comparison

AttributeAcetyl Tetrapeptide-5Oligopeptide-1
CategorySkin & HairSkin & Hair
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionThe peptide is acetyl-beta-alanine-histidine-serine-histidine. The manufacturer's lab work claims three effects: it reduces vascular permeability (less fluid seeping out of small blood vessels, tested in an endothelial cell model), it inhibits glycation (sugar damage to proteins like collagen), and it has some ACE-inhibiting activity that is linked to fluid balance. All of that is in vitro and company-generated. An important reality check: under-eye bags have several causes, and a lot of them in older adults come from fat pads pushing forward and loose skin, not fluid. A peptide aimed at fluid cannot touch fat-pad bags, so even in the best case it fits morning puffiness better than structural eye bags.EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there.
Common Dosing
1% of the Eyeseryl solution in an eye cream
Twice daily
Low parts-per-million concentration in a serum
Once or twice daily
AdministrationTopical (eye creams, gels, serums)Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic
Typical Duration28-60 days in manufacturer studies; ongoing use to maintain any effectStudies typically ran 4 to 12 weeks
Best Time to TakeMorning and evening, gently patted under the eyesEvening skincare routine, or right after an in-clinic procedure
Possible Side Effects
May vary by individual
  • Generally well tolerated
  • Mild stinging or redness around the eyes (uncommon, often from the overall formula)
  • Eye irritation if product gets into the eye
  • Contact allergy possible, as with any skincare ingredient
  • Mild redness, burning or itching (transient)
  • Irritation, especially when used after microneedling
  • Theoretical concern about stimulating existing abnormal or cancerous skin cells (unproven, but untested long term)
  • People with skin cancer history, many atypical moles, or psoriasis should ask a dermatologist first
Research SummaryWe could not find an independent, peer-reviewed clinical trial of acetyl tetrapeptide-5. The evidence is manufacturer data reported in trade publications. Lipotec's best-known study used a 1% Eyeseryl cream on one eye and placebo on the other in male volunteers aged 30 to 65, twice daily for 28 days, and reported about a 30% reduction in under-eye puffiness volume, with most volunteers rating it positively. Another supplier document describes a 60-day study in 20 women using a cream with a very low peptide level, scored from photos by a dermatologist. Other summaries quote different numbers (17% to 21%) from studies we could not trace to an original paper. The studies differ in concentration, sex, length and how puffiness was measured, so they cannot be pooled. Independent ingredient databases rate the evidence as limited for exactly this reason. Bottom line: plausible for mild fluid puffiness, cheap to try in an eye cream, but not a fix for true eye bags and not backed by independent trials.A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question.

Frequently Asked Questions: Acetyl Tetrapeptide-5 vs Oligopeptide-1

What is the difference between Acetyl Tetrapeptide-5 and Oligopeptide-1?

Acetyl Tetrapeptide-5 is a skin & hair peptide that acetyl tetrapeptide-5 is a short synthetic peptide sold by lipotec (now lubrizol) as eyeseryl, made for eye creams that target under-eye puffiness. the pitch is that it reduces fluid leaking into the tissue under the eyes. it is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it. Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. The main differences lie in their mechanisms of action and clinical applications.

Which is better, Acetyl Tetrapeptide-5 or Oligopeptide-1?

Neither is universally "better" - the choice depends on your specific goals. Acetyl Tetrapeptide-5 is typically used for skin & hair purposes, while Oligopeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can Acetyl Tetrapeptide-5 and Oligopeptide-1 be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using Acetyl Tetrapeptide-5 and Oligopeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles